 Shares of GSK GSK, -3.85 fell nearly 4 in London as UBS downgraded the pharmaceutical giant to sell from neutral. We see two factors posing risks to the earnings base longer term blockbuster vaccine Shingrix will exhaust its catch-up patient pool in the U.S. around 27 and HIV product dolutegravir faces patent expiry at the same time. 